Strs Ohio Purchases New Shares in Erasca, Inc. $ERAS

Strs Ohio acquired a new stake in shares of Erasca, Inc. (NASDAQ:ERAS) during the 1st quarter, HoldingsChannel reports. The firm acquired 33,000 shares of the company’s stock, valued at approximately $534,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. EntryPoint Capital LLC purchased a new stake in Erasca in the 4th quarter valued at about $38,000. Stifel Financial Corp purchased a new position in shares of Erasca in the 4th quarter worth approximately $38,000. XTX Topco Ltd bought a new position in shares of Erasca in the fourth quarter valued at approximately $40,000. Mariner LLC purchased a new stake in shares of Erasca during the fourth quarter valued at approximately $40,000. Finally, Cibc World Markets Corp purchased a new stake in shares of Erasca during the fourth quarter valued at approximately $43,000. Hedge funds and other institutional investors own 67.78% of the company’s stock.

Erasca Price Performance

NASDAQ:ERAS opened at $18.53 on Friday. The company has a market capitalization of $5.76 billion, a P/E ratio of -19.92 and a beta of 0.66. The business has a fifty day simple moving average of $13.65 and a two-hundred day simple moving average of $12.81. Erasca, Inc. has a 1 year low of $1.33 and a 1 year high of $24.28.

Erasca (NASDAQ:ERAS) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.48). As a group, analysts anticipate that Erasca, Inc. will post -0.55 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on ERAS. Citigroup reissued a “buy” rating on shares of Erasca in a research report on Friday, March 13th. Bank of America upgraded Erasca from an “underperform” rating to a “neutral” rating and lifted their target price for the stock from $9.00 to $16.00 in a research note on Thursday, June 4th. HC Wainwright boosted their price target on shares of Erasca from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Friday, March 13th. JPMorgan Chase & Co. increased their price target on shares of Erasca from $24.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, March 18th. Finally, Guggenheim raised their price objective on shares of Erasca from $12.00 to $20.00 and gave the stock a “buy” rating in a report on Monday, March 16th. Seven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $20.11.

More Erasca News

Here are the key news stories impacting Erasca this week:

• Positive Sentiment: There were no clear company-specific positive catalysts in the latest news flow, which means investor attention is focused almost entirely on the litigation headlines.
• Neutral Sentiment: Short-interest data released today showed zero reported short interest, so it does not add a meaningful new signal for the stock. Article: Rosen, Recognized Investor Counsel, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ERAS
• Neutral Sentiment: Multiple firms, including Rosen, Robbins LLP, the Schall Law Firm, the Gross Law Firm, and others, issued nearly identical reminders about the pending securities class action and the deadline to seek lead-plaintiff status. Article: Erasca (ERAS) Faces Securities Class Action After Stock Declines 48% on Drug Safety and IP Concerns– HBSS
• Negative Sentiment: The biggest overhang is the allegation that Erasca faced a severe stock drop after Revolution Medicines accused it of patent infringement related to ERAS-0015 and after reports that a patient died about one month after receiving the drug, intensifying legal and safety concerns. Article: Erasca (ERAS) Faces Securities Class Action After Stock Declines 48% on Drug Safety and IP Concerns– HBSS
• Negative Sentiment: The class-action lawsuit and related reminders suggest ongoing legal risk, potential damages, and continued uncertainty for shareholders who bought between January 14, 2025 and April 26, 2026. Article: Erasca, Inc. (ERAS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Erasca Profile

Erasca, Inc is a clinical?stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene?driven and immuno?oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.